Dong Bin, Young Mark, Liu Xueqing, Singh Amar Bahadur, Liu Jingwen
Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304.
Intercept Pharmaceuticals, Inc., San Diego, CA 92121.
J Lipid Res. 2017 Feb;58(2):350-363. doi: 10.1194/jlr.M070888. Epub 2016 Dec 9.
The farnesoid X receptor (FXR) plays critical roles in plasma cholesterol metabolism, in particular HDL-cholesterol (HDL-C) homeostasis. Obeticholic acid (OCA) is a FXR agonist being developed for treating various chronic liver diseases. Previous studies reported inconsistent effects of OCA on regulating plasma cholesterol levels in different animal models and in different patient populations. The mechanisms underlying its divergent effects have not yet been thoroughly investigated. The scavenger receptor class B type I (SR-BI) is a FXR-modulated gene and the major receptor for HDL-C. We investigated the effects of OCA on hepatic SR-BI expression and correlated such effects with plasma HDL-C levels and hepatic cholesterol efflux in hyperlipidemic hamsters. We demonstrated that OCA induced a time-dependent reduction in serum HDL-C levels after 14 days of treatment, which was accompanied by a significant reduction of liver cholesterol content and increases in fecal cholesterol in OCA-treated hamsters. Importantly, hepatic SR-BI mRNA and protein levels in hamsters were increased to 1.9- and 1.8-fold of control by OCA treatment. Further investigations in normolipidemic hamsters did not reveal OCA-induced changes in serum HDL-C levels or hepatic SR-BI expression. We conclude that OCA reduces plasma HDL-C levels and promotes transhepatic cholesterol efflux in hyperlipidemic hamsters via a mechanism involving upregulation of hepatic SR-BI.
法尼醇X受体(FXR)在血浆胆固醇代谢中发挥关键作用,尤其是在高密度脂蛋白胆固醇(HDL-C)稳态方面。奥贝胆酸(OCA)是一种正在开发用于治疗各种慢性肝病的FXR激动剂。先前的研究报道了OCA在不同动物模型和不同患者群体中调节血浆胆固醇水平的效果不一致。其不同作用背后的机制尚未得到充分研究。B1型清道夫受体(SR-BI)是一种受FXR调节的基因,也是HDL-C的主要受体。我们研究了OCA对高脂血症仓鼠肝脏SR-BI表达的影响,并将这些影响与血浆HDL-C水平和肝脏胆固醇流出相关联。我们证明,在治疗14天后,OCA诱导血清HDL-C水平呈时间依赖性降低,同时OCA处理的仓鼠肝脏胆固醇含量显著降低,粪便胆固醇增加。重要的是,OCA处理使仓鼠肝脏SR-BI mRNA和蛋白质水平分别增加至对照的1.9倍和1.8倍。在正常血脂仓鼠中的进一步研究未发现OCA诱导血清HDL-C水平或肝脏SR-BI表达发生变化。我们得出结论,OCA通过上调肝脏SR-BI的机制降低高脂血症仓鼠的血浆HDL-C水平并促进肝脏胆固醇流出。